Mirtazapine add-on therapy in the treatment of schizophrenia with atypical neuroleptics: A double-blind, randomised, placebo controlled trial.

Trial Profile

Mirtazapine add-on therapy in the treatment of schizophrenia with atypical neuroleptics: A double-blind, randomised, placebo controlled trial.

Completed
Phase of Trial: Phase IV

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Mirtazapine (Primary)
  • Indications Schizophrenia
  • Focus Therapeutic Use
  • Most Recent Events

    • 25 May 2011 Additional lead trial centre identified as reported by Australian New Zealand Clinical Trials Registry.
    • 25 May 2011 Actual end date (Jun 2006) added as reported by Australian New Zealand Clinical Trials Registry.
    • 25 May 2011 New source identified and integrated (Australian New Zealand Clinical Trials Registry; ACTRN12605000577617).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top